A study published online today by Biochemical Pharmacology found that several cannabis terpenes enhance how THC activates the body’s cannabinoid receptors, offering new insight into how different cannabis compounds may work together. The study was conducted by researchers from The Open University of Israel.
Terpenes are best known for giving cannabis its aroma and flavor, but researchers note that their pharmacological role remains less established. In this study, scientists examined whether individual terpenes and terpene mixtures could alter THC’s activation of CB1 and CB2 receptors, the two primary receptors in the body’s endocannabinoid system.
Using a cell-based lab model, researchers tested THC alone and in combination with various cannabis terpenes. They found that several terpenes selectively increased THC-driven activation at CB1 or CB2 receptors, with some combinations producing additive effects and others showing signs of synergy.
At CB1 receptors, which are largely associated with THC’s psychoactive effects, researchers found synergistic interactions involving terpenes such as borneol, limonene, sabinene, terpineol, α-pinene and ocimene. At CB2 receptors, which are more closely tied to immune and inflammatory responses, β-caryophyllene and linalool showed synergistic effects with THC.
The study also found that terpene mixtures produced dose-dependent CB1 receptor activation, with several mixtures enhancing THC responses. Researchers said these results suggest that terpenes may act not only as weak activators of cannabinoid receptors on their own, but also as potential modulators of THC activity.
The findings provide a possible scientific framework for cannabinoid-terpene synergy, a concept often discussed in relation to the “entourage effect.” However, researchers emphasized that the results were highly specific to the terpene, receptor and formulation being tested, rather than supporting the idea that all full-spectrum cannabis products work the same way.
Researchers said the findings could help guide the development of more targeted cannabis-based formulations, where specific terpenes are selected to produce desired receptor-level effects.
The study’s authors cautioned that the research was conducted in a lab model, not in humans, and that additional in-vivo and clinical studies are needed to determine whether these receptor-level interactions translate into therapeutic effects, safety benefits or improved tolerability in patients.
